The World Health Organization (WHO) has added three antiretroviral (ARV) medicines manufactured by Aurobindo Pharma to its list.

WHO approved 150 mg, 300 mg tablets of Aurobindo's lamivudine, 300 mg tablets of zidovudine for use by UNAIDS, Unicef and other agencies.

The addition of these medicines will benefit existing AIDS programmes and
procurement schemes. It will reinforce efforts to scale up access to ARVs in
high-burden countries by increasing the choice of quality products in countries which may have only limited capacity to control and monitor medicines.

Currently, approximately 6.5 million people in low- and middle-income countries need ARV therapy.